Meury taking helm at Incyte as Hoppenot retires

Bill Meury is succeeding Hervé Hoppenot as president and CEO of Incyte Corp. (NASDAQ:INCY). Hoppenot is retiring after leading the biotech for 11 years; he is also stepping down as chairman.

Under Hoppenot’s leadership, Incyte has diversified beyond its first approved drug, Jakafi/Jakavi ruxolitinib, while adding indications to the JAK-1/JAK-2 inhibitor’s label. The company now markets seven products across the hematology, oncology and immune/inflammatory areas...